← Who reports today · Health Care
How Johnson & Johnson (JNJ) makes money: Q2 2026 revenue breakdown
US GAAP · $M · vs Q2 2025 · reported 07/15/2026
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. · Wikipedia
More about the company
The company is ranked No. 42 on the 2026 Fortune 500 list of the largest United States corporations. In 2026, the company was ranked 43rd in the Forbes Global 2000. Along with Microsoft, Johnson & Johnson is one of only two U.S.-based companies that has a prime credit rating of AAA from S&P Global. Market share (US pharma & biotech): ≈13% by TTM revenue.
Key growth driver: Innovative Medicine — the fastest-growing revenue line: $16,384, +8% y/y. · by the Q2 2026 report
How does Johnson & Johnson make money?
Johnson & Johnson brought in $25.3 billion of revenue in Q2 2026, up 6.6% year over year. The largest source was Innovative Medicine: $16.4 billion, or 65% of the total, followed by MedTech ($8.93B, 35%). Net income for the quarter was $5.53 billion, down 0.1% year over year.
Revenue by source, Q2 2026
- Innovative Medicine$16.4B · 65% · +7.8%
- MedTech$8.93B · 35% · +4.5%
Shares of $25.3B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.
When is JNJ’s next earnings date?
Tuesday, October 13, 2026confirmed · before market open
Johnson & Johnson (JNJ) is scheduled to report results for the quarter ending Sep 2026 on Oct 13, 2026. Consensus EPS forecast: $2.90 (7 analysts), vs $2.80 in the same quarter last year.
What time does JNJ report? Usually before market open: the last 4 results releases reached the SEC at 7:49 am, 7:35 am, 7:46 am, 7:22 am ET.
Last report: Jul 15, 2026 (Q2 2026) — broken down in the Sankey chart below. Dates and consensus: Nasdaq / Zacks Investment Research; companies do reschedule. Who else reports this week →
All figures in $M.
Revenue
$25,310
+6.6%
Gross profit
$17,259
+7.1%
68.2% margin
Operating income
$6,747
26.7% margin
Net income
$5,534
-0.1%
$2.27 diluted EPS
Verdict: a solid quarter with reported sales up 6.6% to $25.3B led by Innovative Medicine's 7.8% growth (DARZALEX, CARVYKTI, TREMFYA offsetting STELARA erosion), but GAAP net earnings were flat y/y at $5.5B as higher operating costs and below-the-line items offset gross margin gains, while adjusted EPS rose 4.7% and guidance was raised.
Free cash flow ≈$8.7B (YTD, vs $6.2B prior); adjusted net earnings $7,081M (+5.7%); adjusted EPS $2.90 (+4.7%); FY2026 guidance raised to ~$101.1B reported sales and $11.68 adjusted EPS midpoint.
Source and notation
* marks non-cash / ≈ estimated. Source: Johnson & Johnson press release / 10-Q (SEC EDGAR).
Open the chart as a PNG image ↗ · for sharing and presentations · free to reuse, CC BY 4.0
JNJ earnings history: past report dates
| Jul 15, 2026 Wed | 7:49 ambefore market open | Jun 28, 2026 | $25.3B+7% y/y | $2.27−1% y/y |
| Apr 14, 2026 Tue | 7:35 ambefore market open | Mar 29, 2026 | $24.1B+10% y/y | $2.14−53% y/y |
| Jan 21, 2026 Wed | 7:46 ambefore market open | Dec 28, 2025 | ≈$24.6B+9% y/y | ≈$2.08+48% y/y |
| Oct 14, 2025 Tue | 7:22 ambefore market open | Sep 28, 2025 | $24.0B+7% y/y | $2.12+91% y/y |
| Jul 16, 2025 Wed | 8:06 ambefore market open | Jun 29, 2025 | $23.7B+6% y/y | $2.29+19% y/y |
| Apr 15, 2025 Tue | 8:14 ambefore market open | Mar 30, 2025 | $21.9B+2% y/y | $4.54+239% y/y |
| Jan 22, 2025 Wed | 6:35 ambefore market open | Dec 29, 2024 | ≈$22.5B+5% y/y | ≈$1.41−16% y/y |
| Oct 15, 2024 Tue | 7:37 ambefore market open | Sep 29, 2024 | $22.5B+5% y/y | $1.11−89% y/y |
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Johnson & Johnson: 5-year financials
| 2025 | 94,193 | 26,804 | 19,698 |
| 2024 | 88,821 | 14,066 | 19,842 |
| 2023 | 85,159 | 35,153 | 18,248 |
| 2022 | 79,990 | 17,941 | 17,185 |
| 2021 | 78,740 | 20,878 | 19,758 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP).
How we calculate
Figures are the annual report lines as filed, no adjustments. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing.
Corporate governance
2/2good
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
More
- Jul 2026Per the Q2 2026 10-Q, the shareholder suit over talc risk disclosure is unresolved: a class has been certified, the Supreme Court denied review in April 2026, and expert discovery is under way. sec.gov ↗
- Dec 2025Dividend per share: $3.98 (2020), $4.45 (2022), $5.14 (2025) — raised every year (XBRL 10-K). data.sec.gov ↗
- Feb 2026Per the 2025 10-K, one class of shares; diluted share count −9.0% over 5 years (XBRL). sec.gov ↗
Scoring: 2.0, no deductions = 2.0
- Share classes
- Single class of common stock (10-K cover).
- Dilution
- Diluted share count −9.0% over 5 years (including the 2023 Kenvue exchange offer at a 7% discount in participants' favor); SBC 1.4%.
- Disclosure
- 10-Ks and 10-Qs filed on time, audited US GAAP financials; no deduction.
- Dividends
- Dividend raised for 60+ consecutive years: $3.98 (2020) → $5.14 (2025).
- Lawsuits & regulators
- 2018 shareholder class action over concealment of asbestos in talc: class certified, Supreme Court denied review (April 2026), now in the expert stage — unresolved, no deduction under the methodology; talc and opioid suits are product-related.
- Related parties
- No non-arm's-length related-party transactions; the Kenvue exit was done via an exchange offer at a discount in shareholders' favor.
How the score works · checked as of Sep 2026
Johnson & Johnson (JNJ) earnings: FAQ
How does Johnson & Johnson make money?
Johnson & Johnson brought in $25.3 billion of revenue in Q2 2026, up 6.6% year over year. The largest source was Innovative Medicine: $16.4 billion, or 65% of the total, followed by MedTech ($8.93B, 35%). Net income for the quarter was $5.53 billion, down 0.1% year over year.
When is JNJ's next earnings date?
Johnson & Johnson (JNJ) is scheduled to report on Oct 13, 2026, before market open.
What time does JNJ report earnings?
Johnson & Johnson is scheduled to report before market open on Oct 13, 2026. Its last results releases were filed before market open, most recently at 7:49 am ET on Jul 15, 2026.
When did JNJ last report earnings?
Johnson & Johnson reported Q2 2026 results on Jul 15, 2026.
What is the EPS estimate for JNJ's next earnings?
The consensus EPS forecast is $2.90 (7 analysts), vs $2.80 in the same quarter last year.
Where can I find Johnson & Johnson's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to JNJ's filings; this page breaks the latest report down in a Sankey chart.
What was JNJ's net income in Q2 2026?
Johnson & Johnson reported net income of $5,534M for Q2 2026 (-0.1% year over year), under US GAAP.
New to earnings reports? Start with how to read an earnings report.
How this page was made: the figures come from the company's own report on SEC EDGAR; the summary and nuances were drafted by our model from that report. Figures checked against the filing on 08/25/2026. How we make the breakdowns · Report an error
More reports: LLY · Q2 2026 · MCK · Q1 FY2027 · MDT · Q1 2027 · MRK · Q2 2026 · PFE · Q2 2026 · REGN · Q2 2026 · SYK · Q2 2026 · TMO · Q2 2026 · UNH · Q2 2026 · VRTX · Q2 2026 · all reports